» Articles » PMID: 33036386

Clinical Veterinary Boron Neutron Capture Therapy (BNCT) Studies in Dogs with Head and Neck Cancer: Bridging the Gap Between Translational and Clinical Studies

Abstract

Translational Boron Neutron Capture Therapy (BNCT) studies performed by our group and clinical BNCT studies worldwide have shown the therapeutic efficacy of BNCT for head and neck cancer. The present BNCT studies in veterinary patients with head and neck cancer were performed to optimize the therapeutic efficacy of BNCT, contribute towards exploring the role of BNCT in veterinary medicine, put in place technical aspects for an upcoming clinical trial of BNCT for head and neck cancer at the RA-6 Nuclear Reactor, and assess the feasibility of employing the existing B2 beam to treat large, deep-seated tumors. Five dogs with head and neck cancer with no other therapeutic option were treated with two applications of BNCT mediated by boronophenyl-alanine (BPA) separated by 3-5 weeks. Two to three portals per BNCT application were used to achieve a potentially therapeutic dose over the tumor without exceeding normal tissue tolerance. Clinical and Computed Tomography results evidenced partial tumor control in all cases, with slight-moderate mucositis, excellent life quality, and prolongation in the survival time estimated at recruitment. These exploratory studies show the potential value of BNCT in veterinary medicine and contribute towards initiating a clinical BNCT trial for head and neck cancer at the RA-6 clinical facility.

Citing Articles

Current Insights into the Radiobiology of Boron Neutron Capture Therapy and the Potential for Further Improving Biological Effectiveness.

Punshon L, Fabbrizi M, Phoenix B, Green S, Parsons J Cells. 2025; 13(24.

PMID: 39768156 PMC: 11674336. DOI: 10.3390/cells13242065.


Cobaltabis(Dicarbollide) [-COSAN] for Boron Neutron Capture Therapy of Head and Neck Cancer: Biodistribution and Irradiation Studies in an Experimental Oral Cancer Model.

Palmieri M, Monti Hughes A, Trivillin V, Garabalino M, Ramos P, Thorp S Pharmaceuticals (Basel). 2024; 17(10).

PMID: 39459007 PMC: 11510372. DOI: 10.3390/ph17101367.


Using the photon isoeffective dose formalism to compare and combine BNCT and CIRT in a head and neck tumour.

Postuma I, Magni C, Marcaccio B, Fatemi S, Vercesi V, Ciocca M Sci Rep. 2024; 14(1):418.

PMID: 38172585 PMC: 10764928. DOI: 10.1038/s41598-023-50522-5.


The role of radiolabeling in BNCT tracers for enhanced dosimetry and treatment planning.

Mushtaq S, Ae P, Kim J, Lee K, Kim K Theranostics. 2023; 13(15):5247-5265.

PMID: 37908724 PMC: 10614688. DOI: 10.7150/thno.88998.


Enhancement in the Therapeutic Efficacy of In Vivo BNCT Mediated by GB-10 with Electroporation in a Model of Oral Cancer.

Olaiz N, Monti Hughes A, Pozzi E, Thorp S, Curotto P, Trivillin V Cells. 2023; 12(9).

PMID: 37174642 PMC: 10177359. DOI: 10.3390/cells12091241.


References
1.
Coderre J, Elowitz E, Chadha M, Bergland R, Capala J, JOEL D . Boron neutron capture therapy for glioblastoma multiforme using p-boronophenylalanine and epithermal neutrons: trial design and early clinical results. J Neurooncol. 1997; 33(1-2):141-52. DOI: 10.1023/a:1005741919442. View

2.
Almela R, Anson A . A Review of Immunotherapeutic Strategies in Canine Malignant Melanoma. Vet Sci. 2019; 6(1). PMC: 6466282. DOI: 10.3390/vetsci6010015. View

3.
Takeuchi A . Possible application of boron neutron capture therapy to canine osteosarcoma. Nihon Juigaku Zasshi. 1985; 47(6):869-78. DOI: 10.1292/jvms1939.47.869. View

4.
Axiak-Bechtel S, Maitz C, Selting K, Bryan J . Preclinical imaging and treatment of cancer: the use of animal models beyond rodents. Q J Nucl Med Mol Imaging. 2015; 59(3):303-16. View

5.
Kreimann E, Itoiz M, Longhino J, Blaumann H, Calzetta O, Schwint A . Boron neutron capture therapy for the treatment of oral cancer in the hamster cheek pouch model. Cancer Res. 2001; 61(24):8638-42. View